Oppenheimer Believes K2M Group Holdings (NASDAQ: KTWO) Still Has Room to Grow

By Carrie Williams

In a report released today, Steven Lichtman from Oppenheimer reiterated a Buy rating on K2M Group Holdings (NASDAQ: KTWO). The company’s shares opened today at $23.27, close to its 52-week high of $23.92.

According to TipRanks.com, Lichtman is ranked 0 out of 5 stars with an average return of -4.0% and a 55.3% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Integra Lifesciences.

K2M Group Holdings has an analyst consensus of Strong Buy, with a price target consensus of $26.75.

Based on K2M Group Holdings’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $61.89 million and GAAP net loss of $10.87 million. In comparison, last year the company earned revenue of $56.31 million and had a GAAP net loss of $10.19 million.

Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

K2M Group Holdings, Inc. is a global medical device company. It focused on designing, developing and commercializing innovative and proprietary complex spine technologies and techniques. The company’s complex spine products are used by spine surgeons to treat some of the most difficult and challenging spinal pathologies, such as deformity, trauma and tumor. Its products consist of implants, disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. K2M Group Holdings was founded by John Philip Kostuik and Eric D. Major in June 29, 2010 and is headquartered in Leesburg, VA.,00CRV6-E